Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 47100
5mg	JPY 30200
50mg	JPY 163000
200mg	JPY 412000

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(463)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明

ターゲット

BTK ^[1] (Cell-free assay)	BLK ^[1] (Cell-free assay)	Bmx ^[1] (Cell-free assay)	CSK ^[1] (Cell-free assay)	FGR ^[1] (Cell-free assay)	もっとクリックする
0.5 nM	0.5 nM	0.8 nM	2.3 nM	2.3 nM	もっとクリックする

体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. ^[1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. ^[2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human Rec1 cells	NEfwUYJHfW6ldHnvckBie3OjeR?=	MnvWNk42KM7:TR?=	NGfQT5Q3KGh?	M{fudWlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
human WSU-NHL cells	M3;oVmN6fG:2b4jpZ:Kh[XO\|YYm=		MVG3NkBp	MlzlR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gW3NWNU6KTDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC5JO69VQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human SU-DHL6 cells	MULDfZRwfG:6aXRCpIF{e2G7		MmTtO\|IhcA>?	MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUEx4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwNUig{txONg>?	NGW2e3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human DOHH2 cells	M3nnN2N6fG:2b4jpZ:Kh[XO\|YYm=		NE\Fbm04OiCq	MonjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSG9JUDJiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MTFOwG0v	Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 cells	NIXEZndHfW6ldHnvckBie3OjeR?=		NVLoUlZCOSCq	NHnOOYtKdmirYnn0bY9vKG:oIFzZUk1CKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZYZ1\XJiNkCgcYlveyCkeTDUVk1HWkWWIFHzd4F6NCCLQ{WwQVAvOiEQvF2u	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
human Ramos cells	Mn\oSpVv[3Srb36gZZN{[Xl?		M2\jZ\|EhcA>?	M1LpdmlvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6=	MmX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human Pfeiffer cells	NGLBZ3dHfW6ldHnvckBie3OjeR?=		NVKy[oZuPzJiaB?=	NH:0SZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR\mWrZn\ldkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yJI5ONg>?	NFi0OFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 cells	NUHQdJl7TnWwY4Tpc44h[XO\|YYm=		NV21OIJTOSCq	NHzFdGlKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHytcIVv\3SqIFLUT{BmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IIXzbY5oKE[DTT3TdoN1cWSnIIDldJRq\GViYYOgd5Vje3S{YYTlJIFnfGW{IE[wJI1qdnNiYomgWHIuTlKHVDDBd5Nige,:jDDJR\|UxRTBwNTDuUU4>	M2rLVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Sf9 insect cells	M13YN2Z2dmO2aX;uJIF{e2G7		NGXnVGk3OCCvaX7z	MknhTWM2OCB;IECuNFAxOyEQvF2=	M{Hr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
sf9 cells	MkC1SpVv[3Srb36gZZN{[Xl?			MlzvTWM2OCB;IECuNFAxOyEQvF2=	NVXXVYNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
Sf9 insect cells	NYLBeHVlTnWwY4Tpc44h[XO\|YYm=		M3PkVVYxKG2rboO=	NHz6Wo9KSzVyIE2gNE4xODB\|NDFOwG0>	M374bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells	MYfGeY5kfGmxbjDhd5NigQ>?		MljNOlAhdWmwcx?=	MknGTWM2OCB;IECuNFAxOzRizszN	NGi5XII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNlk1Pid-Mki0N\|I6PDZ:L3G+
Sf9 insect cells	MnnOSpVv[3Srb36gZZN{[Xl?		NGjGNWI3OCCvaX7z	MV3JR\|UxKD1iMD6wNFA{PCEQvF2=	NVzFT2tURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
Sf9 cells	M{GwfWZ2dmO2aX;uJIF{e2G7		NH3kNoM3OCCvaX7z	NFfQdlhKSzVyIE2gNE4xODB2IN88US=>	NXj5SVI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
Sf9 cells	NHX2ZXhHfW6ldHnvckBie3OjeR?=		NUfvbWhJPjBibXnudy=>	NH64NJRKSzVyIE2gNE4xODB3IN88US=>	M1fmOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Ramos cells	MV;GeY5kfGmxbjDhd5NigQ>?		NVnQZpA4OSCq	NXnLOFFPUUN3MDC9JFAvODByNTFOwG0>	NUTjfYdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells	NFXSenFHfW6ldHnvckBie3OjeR?=		Mnv3OlAhdWmwcx?=	M{DBe2lEPTBiPTCwMlAxOSEQvF2=	NH:ybJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Pfeiffer cells	M2PSdGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWnI[WtnPzJiaB?=	MVjHTVUxKD1iMD6wNFIh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
B cells	MV;GeY5kfGmxbjDhd5NigQ>?		M4OyZVEhcA>?	NV34OlhwUUN3MDC9JFAvODB2NjFOwG0>	NW\tTXI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyPVA6QDhpPkOwNlkxQTh6PD;hQi=>
Sf9 insect cells	M2mzfGZ2dmO2aX;uJIF{e2G7		NGC2[VczKHSxIE[wJI1qdnN?	MVfLbUA:KDBwMEC0PEDPxE1?	NEfydYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	NYf6b25MTnWwY4Tpc44h[XO\|YYm=		MUKxJIg>	MlzPTWM2OCB;IECuNFA4PSEQvF2=	NEDG[IY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells	MYDGeY5kfGmxbjDhd5NigQ>?		MXy2NEBucW6\|	M{HIfmlEPTBiPTCwMlAxQCEQvF2=	NGDhPHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
TMD8 cells	NWK5epdTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NGnpZos4OiCq	NH:1e4ZKSzVyIE2gNE4xOSEQvF2=	M{HSUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
CD19+ B cells	NYPxcGl3TnWwY4Tpc44h[XO\|YYm=		NFzpUW0yKGh?	MWLJR\|UxKD1iMD6wNVIh\|ryP	NHK5XZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1O\|k5Oid-Mkm0OVc6QDJ:L3G+
Sf9 insect cells	MWDGeY5kfGmxbjDhd5NigQ>?		NY\CVHpVPjBibXnudy=>	NXXlOWFnUUN3MDC9JFAvODF{IN88US=>	MoDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells	NIjHS45HfW6ldHnvckBie3OjeR?=		MnHuNUBp	NHXuWpFKSzVyIE2gNE4xOTRizszN	NH;JZmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells	M4XkO2Z2dmO2aX;uJIF{e2G7		MljCNUBp	MoC3TWM2OCB;IECuNFE1PCEQvF2=	NHfyVHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUexOVAzOyd-Mkm3NVUxOjN:L3G+
Sf9 insect cells	MnW1SpVv[3Srb36gZZN{[Xl?		MWi2NEBucW6\|	M{nuWWlEPTBiPTCwMlAyPjFizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
HCC827 cells	NXPnZWxKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MWW3NkBp	NU\QXY5WUUN3MDC9JFAvODN7IN88US=>	NYfDfmdmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N\|Q2QDFpPkK4O\|M1PThzPD;hQi=>
PC9 cells	M3;W[GZ2dmO2aX;uJIF{e2G7		MXG3NkBp	NX;oOINJT0l3MDC9JFAvODVizszN	MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells	NX7sSGRITnWwY4Tpc44h[XO\|YYm=		NX;xOZdvPjBibXnudy=>	MkL3TWM2OCB;IECuNUDPxE1?	NWmyem5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
H3255 cells	MmPZSpVv[3Srb36gZZN{[Xl?		NHW5N2Y4OiCq	Mn7XS2k2OCB;IECuNVEh\|ryP	NEPkd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BaF3 cells	NIf1Xo5HfW6ldHnvckBie3OjeR?=		MnH4O\|IhcA>?	NULQT2NuT0l3MDC9JFAvOTJizszN	M1nZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells	NHj0dlFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NHX5PWU4OiCq	MmPSS2k2OCB;IECuNVIh\|ryP	NIfHNYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Sf9 insect cells	MUPGeY5kfGmxbjDhd5NigQ>?		M{nzfFYxKG2rboO=	NWq0boFpUUN3MDC9JFAvOTJ\|IN88US=>	NHjYemc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Sf9 insect cells	MVrGeY5kfGmxbjDhd5NigQ>?		M{LQWlYxKG2rboO=	NVOxUFJoUUN3MDC9JFAvOTR4IN88US=>	M{LmU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells	MlrSSpVv[3Srb36gZZN{[Xl?		MnHhO\|IhcA>?	NHnJcFlIUTVyIE2gNE4yPiEQvF2=	NISyOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells	MY\GeY5kfGmxbjDhd5NigQ>?		MUi2NEBucW6\|	MXvJR\|UxKD1iMD6yJO69VQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
MV411 cells	NHPYcHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NWDieZl3T0l3MDC9JFAvOjVizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
MV4-11 cells	NYTjXlJSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MlnhO\|IhcA>?	NXLJb2tIT0l3MDC9JFAvOzNizszN	MnfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells	M2rpSmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M{TuS\|czKGh?	NIjiW\|dIUTVyIE2gNE4{OyEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
DOHH2 cells	NXjNbWNCS3m2b4TvfIlkcXS7IHHzd4F6		MlHNO\|IhcA>?	MlKwS2k2OCB;IECuOFEh\|ryP	M1zFWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
HCC827 cells	NF;jOpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1XUd\|k3KGh?	M{[1XGVEPTBiPTCwMlQ2KM7:TR?=	Mmi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL6 cells	NUnENIJFS3m2b4TvfIlkcXS7IHHzd4F6		M3TOT\|czKGh?	NWr6PFNpT0l3MDC9JFAvPThizszN	NGj4eGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
M07e cells	NEL5blJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NYfwcll5T0l3MDC9JFAvPTlizszN	NV3Oem1yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
NCI-H1975 cells	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MmPGPVYhcA>?	NUTXbnVlTUN3MDC9JFAvPjRizszN	NXmzUZp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL-2 cells	Mn\5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NH3J[VFIUTVyIE2gNE43PCEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
HEK293T cells	M3XjOGZ2dmO2aX;uJIF{e2G7		MXSxJIg>	NFrMSIdKSzVyIE2gNE46KM7:TR?=	M3i1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiwNlYyLz5{OEK4NFI3OTxxYU6=
Ramos cells	M3uycmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MkToO\|IhcA>?	MXfJR\|UxKD1iMD65NkDPxE1?	Mnm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
BA/F3 cells	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NVK2cVZlPzJiaB?=	NYTw[IJZUUN3MDC9JFEh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3OEWyNUc,OjZ{NUi1NlE9N2F-
WSU-NHL cells	M2jpXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1js[FczKGh?	NVv1eJZxT0l3MDC9JFEvODlizszN	M3fm[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
NCI-H1975 cells	NGXs[GlHfW6ldHnvckBie3OjeR?=		M1[yVlczKGh?	MVnHTVUxKD1iMT6yJO69VQ>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 cells	NIHMS4FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M{TO[lczKGh?	Ml\FTWM2OCB;IEGuNlch\|ryP	NIK0PVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N\|Q2QDF:L3G+
Raji cells	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MWW0PEBp	MmW4TWM2OCB;IEGuOFkh\|ryP	Mn7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
Pfeiffer cells	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NHnxTpVIUTVyIE2gNU43KM7:TR?=	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
A431 cells	MnTYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MU[5OkBp	NYHKdos2TUN3MDC9JFIvOzhizszN	MlnSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
BAF3 cells	Mn7URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NYjMXGM4PzJiaB?=	MmrPS2k2OCB;IEKuOUDPxE1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937 cells	NHXFbYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NGPKclRIUTVyIE2gNk46KM7:TR?=	NUK4eYx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
NB4 cells	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NIXMfpZIUTVyIE2gN{DPxE1?	NFnjS\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	NWjMd5ZuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NYOyPFE3T0l3MDC9JFMvPCEQvF2=	M1X0O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
SKM1 cells	M1\u[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MXjHTVUxKD1iMz62JO69VQ>?	NHrOUow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
U2932 cells	NHm4VoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MoHIS2k2OCB;IESuOEDPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
Ramos cells	MlPQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M1LFXVczKGh?	NUL4ToVnUUN3MDC9JFUvOTRizszN	Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Ramos cells	MkHCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		Ml;2OFghcA>?	NF7sUppKSzVyIE2gOU4yPCEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN\|c9N2F-
Ramos cells	Mnj4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NGHBfYg1QCCq	M4HjZmlEPTBiPTC1Mlg5KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|Mkm0Okc,Ojh2M{K5OFY9N2F-
Ramos cells	NX\lXXBlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUPqXGx3PzJiaB?=	MWnJR\|UxKD1iNj62NkDPxE1?	MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN\|YoRjJ7MUS2NVM3RC:jPh?=
K562 cells	MkLNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MoXZOFghcA>?	NX23NGkyUUN3MDC9JFcvPSEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells	MlT3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NYPWTGhtPDhiaB?=	NW\lUGlrUUN3MDC9JFgh\|ryP	M37TSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5\|MEC3O\|YxQDxxYU6=
Ramos cells	NUjSPGtSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M1\JUVQ5KGh?	MVXJR\|UxKD1iOD6xNUDPxE1?	NX\ieGtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
Ramos cells	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MUC0PEBp	M2Hj[GlEPTBiPTC4MlI3KM7:TR?=	M3PBcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O\|I6PTxxYU6=
OCI-AML3 cells	NV[5[GhGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			MYDHTVUxKD1iOT6yJO69VQ>?	MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
BAF3 cells	NYLudZMzS3m2b4TvfIlkcXS7IHHzd4F6		M2H4UVczKGh?	MWnHTVUxKD1iMUCg{txO	NXvvOnkxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N\|A2PTNpPkK2OlMxPTV\|PD;hQi=>
BAF3 cells	NYqzOW9nSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NGOwbWY4OiCq	NVm1bHFzT0l3MDC9JFExKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3 cells	NX7GVZNpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1fad\|czKGh?	MnfXS2k2OCB;IEGwJO69VQ>?	M1nlN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NAMALWA cells	NX7iOmRkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M1vh[VczKGh?	NIS1[WpKSzVyIE2gNVAvPDVizszN	MoHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN\|YoRjJ7MUS2NVM3RC:jPh?=
Ramos cells	NGHsd4xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1nNbVQ5KGh?	MmHyTWM2OCB;IEGyMlYh\|ryP	MoOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO\|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells	M321NGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MoHWOFghcA>?	NGX6c5pKSzVyIE2gNVQvOiEQvF2=	NGO1R4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Raji cells	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MkPHOFghcA>?	MYLJR\|UxKD1iMUWuNkDPxE1?	M1jwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M3Lz5{N{m5OFc{PjxxYU6=
MIAPaCa2 cells	NW\zXIE2S3m2b4TvfIlkcXS7IHHzd4F6		MYezJIRigXN?	MkTETWM2OCB;IEG2MlYh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
HeLa cells	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=		NWXpT3ZUOyCmYYnz	NETnbGtKSzVyIE2gNVYvQCEQvF2=	NYr6dW15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO\|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NILFTng1QCCq	MkXQTWM2OCB;IEG5MlMh\|ryP	NEfTRYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells	NGj2[3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		Mo[xOFghcA>?	NW\rWnplUUN3MDC9JFE6NjNizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells	M1jieWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M1frVVczKGh?	MmXDTWM2OCB;IEG5MlUh\|ryP	NUDwdoh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
Raji cells	Mo\wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NHjBPIc1QCCq	MlThTWM2OCB;IEG5MlUh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN\|c9N2F-
NAMALWA cells	NXXCUmg3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		Mn\0O\|IhcA>?	MYDJR\|UxKD1iMUmuOkDPxE1?	MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
A2780 cells	M3TzbWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MVizJIRigXN?	MUfFR\|UxKD1iMkCuNUDPxE1?	NUnR[FU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO\|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells	NXnsXpBsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MkK3O\|IhcA>?	NF3RUJpKSzVyIE2gNlAvQDhizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
A549 cells	NVTI[YQ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXXXflZ[PzJiaB?=	MVzJR\|UxKD1iMkGuO\|kh\|ryP	MknqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
SW480 cells	MorYR5l1d3SxeHnjbZR6KGG\|c3H5		MUKzJIRigXN?	M3X2XGlEPTBiPTCyOU43KM7:TR?=	NXHvZmlpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO\|czOjhpPkK3NFc4OjJ6PD;hQi=>
Ramos cells	Ml3QR5l1d3SxeHnjbZR6KGG\|c3H5		NYjN[IV6OjRiaB?=	MXrJR\|UxKD1iMkiuO{DPxE1?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5NE[3OUc,Ojh{N{S2O\|U9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pEGFR(Tyr1068) / EGFR; PubMed: 28061447 Oncotarget Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment. pBTK / pPLCγ2 / pAKT / pERK / pJNK; PubMed: 23940282 Blood Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.	28061447 23940282
Immunofluorescence	CD11b; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm. COX-2; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies.	30231870
ELISA	hTNFα; PubMed: 26627823 J Biol Chem PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3). IL-10; PubMed: 27792904 Virology LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.	26627823 27792904

体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. ^[1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. ^[4]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Kinase Assays : In vitro kinase IC50 values are measured using ³³P filtration binding assay after 1 hour incubation of kinase, ³³P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験： ^[2]	- 合併細胞株： Chronic lymphocytic leukemia (CLL) cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： MRL-Fas(lpr) lupus model and collagen-induced arthritis model. 投薬量： ≤50 mg/kg 投与方法： Administered via p.o. (参考用のみ)

参考

[4] Ponader S, et al. Blood. 2012, 119(5), 1182-1189.

- 合併

溶解度 (25°C)

体外	DMSO	88 mg/mL (199.77 mM)
	Water	Insoluble
	Ethanol	'45 mg/mL warmed '45
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

分子量	440.5
化学式	C₂₅H₂₄N₆O₂
CAS No.	936563-96-1
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04665115	Withdrawn	Drug: Ibrutinib\|Other: Quality-of-Life Assessment	Asymptomatic COVID-19 Infection Laboratory-Confirmed\|B-Cell Neoplasm\|Chronic Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma\|Symptomatic COVID-19 Infection Laboratory-Confirmed\|Waldenstrom Macroglobulinemia	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	December 2021	Phase 2
NCT05105841	Recruiting	Drug: Venetoclax\|Drug: Ibrutinib\|Drug: Obinutuzumab	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	AbbVie	November 8 2021	Phase 2
NCT04876092	Recruiting	Drug: JNJ-67856633\|Drug: Ibrutinib	Leukemia Lymphocytic Chronic B-Cell\|Lymphoma Non-Hodgkin	Janssen Research & Development LLC	July 28 2021	Phase 1
NCT04294641	Recruiting	Drug: Ibrutinib	Chronic GVHD	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	May 10 2021	Phase 2
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
How to reconstitute the compound S2680 for in vivo studies?
回答：
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

研究分野別

製品類型

Ibrutinib (PCI-32765)

文献中Selleckの製品使用例(463)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技術サポート

よくある質問（FAQ）